1.38
price down icon4.83%   -0.07
after-market アフターアワーズ: 1.35 -0.03 -2.17%
loading
前日終値:
$1.45
開ける:
$1.41
24時間の取引高:
1.61M
Relative Volume:
1.01
時価総額:
$159.19M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.8364
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-11.54%
1か月 パフォーマンス:
+31.43%
6か月 パフォーマンス:
+36.63%
1年 パフォーマンス:
+52.47%
1日の値動き範囲:
Value
$1.34
$1.43
1週間の範囲:
Value
$1.332
$1.60
52週間の値動き範囲:
Value
$0.6611
$1.9399

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1108)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2025-08-08
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.38 167.26M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.82 121.40B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
764.93 83.25B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
728.11 46.39B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.51 43.41B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
292.94 33.09B 5.36B 287.73M 924.18M 2.5229

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-31 アップグレード H.C. Wainwright Neutral → Buy
2025-10-27 アップグレード Wedbush Neutral → Outperform
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Mar 04, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 04, 2026
pulisher
Mar 03, 2026

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire

Mar 03, 2026
pulisher
Mar 03, 2026

Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo

Mar 03, 2026
pulisher
Mar 03, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga

Mar 03, 2026
pulisher
Mar 03, 2026

FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 01, 2026

Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn

Mar 01, 2026
pulisher
Feb 28, 2026

Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail

Feb 28, 2026
pulisher
Feb 27, 2026

Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView

Feb 27, 2026
pulisher
Feb 26, 2026

Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics: Fourth Quarter Earnings Overview - Bitget

Feb 26, 2026
pulisher
Feb 26, 2026

Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget

Feb 26, 2026
pulisher
Feb 26, 2026

FATE THERAPEUTICS INC SEC 10-K Report - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics reports lower Q4 collaboration revenue - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

Form 10-K FATE THERAPEUTICS INC For: Dec 31 - StreetInsider

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings Summary: Fate Therapeutics Q4 - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Off-the-shelf CAR-T goes outpatient as Fate cuts hospital stays, chemo - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability - Sahm

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World

Feb 26, 2026
pulisher
Feb 25, 2026

Bond Watch: What are AFBIs technical support levels2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Aug Patterns: Will Fate Therapeutics Inc outperform small cap indexes2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World

Feb 25, 2026
pulisher
Feb 24, 2026

Aug PreEarnings: Can Roundhill Etf Trust Roundhill Aapl Weeklypay Etf reach all time highs this yearQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 21, 2026

Will Fate Therapeutics Inc. outperform the market in YEARTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru

Feb 21, 2026
pulisher
Feb 20, 2026

Is Fate Therapeutics Inc. stock risky to hold now2025 Geopolitical Influence & Advanced Technical Signal Analysis - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Is Fate Therapeutics Inc. subject to activist investor interestJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru

Feb 20, 2026
pulisher
Feb 19, 2026

MSN Money - MSN

Feb 19, 2026
pulisher
Feb 18, 2026

Can Fate Therapeutics Inc. lead its sector in growthJuly 2025 Technicals & Fast Entry and Exit Trade Plans - mfd.ru

Feb 18, 2026
pulisher
Feb 17, 2026

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GuruFocus

Feb 17, 2026
pulisher
Feb 16, 2026

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times

Feb 16, 2026
pulisher
Feb 14, 2026

What analysts say about Fate Therapeutics Inc. stock2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru

Feb 14, 2026
pulisher
Feb 13, 2026

FATE PE Ratio & Valuation, Is FATE Overvalued - Intellectia AI

Feb 13, 2026
pulisher
Feb 13, 2026

S P Trends: What analysts say about Fate Therapeutics Inc stock2025 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn

Feb 13, 2026
pulisher
Feb 12, 2026

Gains Recap: Can Fate Therapeutics Inc lead its sector in growthMarket Movers & Community Verified Watchlist Alerts - baoquankhu1.vn

Feb 12, 2026
pulisher
Feb 12, 2026

The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant

Feb 12, 2026
pulisher
Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World

Feb 10, 2026
pulisher
Feb 08, 2026

Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Feb 08, 2026
pulisher
Jan 31, 2026

Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Jan 31, 2026
pulisher
Jan 30, 2026

The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode? - AD HOC NEWS

Jan 30, 2026
pulisher
Jan 22, 2026

Guidance Update: What analysts say about Fate Therapeutics Inc stock2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 20, 2026

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened - Defense World

Jan 20, 2026
pulisher
Jan 17, 2026

Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st

Jan 17, 2026

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
大文字化:     |  ボリューム (24 時間):